Valneva

Valneva R&D per Employee

The R&D Spending per Employee of Valneva (VLA.PA) as of Sep 16, 2026 is 167,919.29 EUR. In the previous year, R&D Spending per Employee was 145,950.79 EUR — a change of 15.05% (higher).

R&D per Employee

167,919.29EUR

YoY

15.05%

Last updated:

R&D Spending per Employee of Valneva is 2026 167,919.29 EUR. R&D Spending per Employee of Valneva was 2025 145,950.79 EUR. It decreases by 15.05% higher compared to the previous year.

The Valneva R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
24,001.97 EUR
Jan 1, 2019
74,572.83 EUR
Jan 1, 2020
166,248.03 EUR
Jan 1, 2021
341,108.27 EUR
Jan 1, 2022
206,539.37 EUR
Jan 1, 2023
117,901.57 EUR
Jan 1, 2024
145,950.79 EUR
Jan 1, 2025
167,919.29 EUR
The Valneva R&D per Employee history
YEARR&D per EmployeeYoY
167,919.29EUR+15.05%
145,950.79EUR+23.79%
117,901.57EUR-42.92%
206,539.37EUR-39.45%
341,108.27EUR+105.18%
166,248.03EUR+122.93%
74,572.83EUR+210.69%
24,001.97EUR-47.79%
45,976.38EUR-5.01%
48,403.54EUR-3.07%
49,935.04EUR+14.05%
43,783.46EUR
Access this data via the Eulerpool API

Valneva Stock analysis

What does Valneva do? Valneva SE is a biopharmaceutical company specializing in the development, production, and marketing of vaccines for humans and animals. The company was founded in 2013 through the merger of French biotech company Vivalis and Austrian biotech company Intercell. Valneva focuses on developing vaccines for infectious diseases with a significant global burden but limited commercial demand. They work closely with governments and international organizations to improve access to their vaccines in developing countries. Valneva also has a strong presence in the animal vaccine market, producing vaccines for diseases in livestock and pets. They have developed and marketed several vaccines, including Ixiaro for Japanese encephalitis and VLA15, a vaccine candidate for Lyme disease. Overall, Valneva is an international company with an impressive pipeline of vaccine candidates and a commitment to addressing global health needs. Valneva is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valneva stock

R&D Spending per Employee of Valneva is 167,919.29 EUR in 2026.

R&D Spending per Employee of Valneva changed from 145,950.79 EUR to 167,919.29 EUR, representing a 15.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Valneva since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Valneva historically and in real time.

Access this data via the Eulerpool API

Workforce — Valneva

All Key Metrics — Valneva